NO965207L - Sammensetning for indusering av mukosal immunrespons - Google Patents

Sammensetning for indusering av mukosal immunrespons

Info

Publication number
NO965207L
NO965207L NO965207A NO965207A NO965207L NO 965207 L NO965207 L NO 965207L NO 965207 A NO965207 A NO 965207A NO 965207 A NO965207 A NO 965207A NO 965207 L NO965207 L NO 965207L
Authority
NO
Norway
Prior art keywords
immune response
antigen
inducing
composition
site
Prior art date
Application number
NO965207A
Other languages
English (en)
Other versions
NO965207D0 (no
Inventor
Bruno Guy
Jean Haensler
Marie-Jose Quentin-Millet
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of NO965207D0 publication Critical patent/NO965207D0/no
Publication of NO965207L publication Critical patent/NO965207L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Farmasøytisk sammensetning er beskrevet for indusering av en beskyttende immunrespons overfor et antigen i et mukosal effektor sete i et vertspattedyr. Sammensetningen innbefatter minst to identiske eller forskjellige komponenter som hver inneholder et immunrespons induserende middel valgt fra antigen, forutsatt at antigenet er et proteinantigen, og en ekspresjonskassett som har evne til å uttrykke antigenet, for samtidig eller påfølgende administrering. En av komponentene er formulert for nasal/oral levering slik at induseringsmiddelet blir målsøkt til immunrespons induserende sete (er) i nese/oral hulrom/pharynx eller spyttkjertler, mens den andre komponenten er formulert for egnet mukosal levering forskjellig fra nasal levering slik at induseringsmiddelet blir målsøkt til immunresponsinduserende sete(er) ved effektorsetet, hvor en immunrespons er ønsket. Nevnte sammensetning kan eventuelt også innbefatte en tredje komponent som er identisk med eller forskjellig fra de første to komponentene og formulert for systemisk administrering.
NO965207A 1995-04-07 1996-12-05 Sammensetning for indusering av mukosal immunrespons NO965207L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504433A FR2732605B1 (fr) 1995-04-07 1995-04-07 Composition destinee a l'induction d'une reponse immunitaire mucosale
PCT/FR1996/000534 WO1996031235A1 (fr) 1995-04-07 1996-04-09 Composition destinee a l'induction d'une reponse immunitaire mucosale

Publications (2)

Publication Number Publication Date
NO965207D0 NO965207D0 (no) 1996-12-05
NO965207L true NO965207L (no) 1996-12-05

Family

ID=9478070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965207A NO965207L (no) 1995-04-07 1996-12-05 Sammensetning for indusering av mukosal immunrespons

Country Status (10)

Country Link
US (1) US6126938A (no)
EP (1) EP0765170A1 (no)
JP (1) JPH10501556A (no)
AU (1) AU5504996A (no)
CA (1) CA2192473A1 (no)
FR (1) FR2732605B1 (no)
HU (1) HUP9700037A3 (no)
NO (1) NO965207L (no)
NZ (1) NZ306483A (no)
WO (1) WO1996031235A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
NZ307017A (en) * 1995-04-28 1999-07-29 Oravax Inc Vaccine containing multimeric complexes of helicobacter urease, composition of antigen (from gastroduodenal pathogen) and antibiotic, antisecretory agent, and/or bismuth salt
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
US6248551B1 (en) 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
KR20010020418A (ko) * 1997-04-30 2001-03-15 마리에 폴린 에이로레 Ｔｈ1-형 면역 보강제를 포함하는 항헬리코박터 백신 조성물
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
EP1073745B1 (en) * 1998-04-30 2004-12-01 Chiron S.r.l. Immunization against and treatment for infection by h. pylori
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6576244B1 (en) * 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US20040157277A1 (en) * 2002-03-08 2004-08-12 Clancy Robert Llewellyn Methods for predicting and/or diagnosing the risk of gastric cancer
AUPQ854100A0 (en) * 2000-07-03 2000-07-27 Helirad Pty Ltd Methods for monitoring treatment of helicobacter infection
US20040033240A1 (en) * 2000-07-05 2004-02-19 Bruno Guy Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
SI1530482T1 (sl) * 2002-07-18 2014-03-31 Helix Biopharma Corp. Uporaba ureaze za inhibiranje rasti rakavih celic
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
MXPA06001674A (es) 2003-08-12 2006-05-12 3M Innovative Properties Co Compuestos que contienen imidazo hidroxilamina-sustituidos.
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1660026A4 (en) 2003-09-05 2008-07-16 3M Innovative Properties Co TREATMENT FOR CD5 + B CELL LYMPHOMA
AU2004278014B2 (en) 2003-10-03 2011-04-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
US7198785B2 (en) * 2003-12-09 2007-04-03 Brown University Systems and methods related to degradation of uremic toxins
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
US20080119508A1 (en) * 2004-12-30 2008-05-22 3M Innovative Properties Company Multi-Route Administration Of Immune Response Modifier Compounds
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
KR100333113B1 (ko) * 1993-07-27 2002-11-27 시에스엘 리미티드 헬리코박터피롤리관련위십이지장질환의치료방법
JPH09512177A (ja) * 1994-04-29 1997-12-09 ファルマシア・アンド・アップジョン・カンパニー ネコ免疫不全ウイルスワクチン
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
GB9503824D0 (en) 1995-02-25 1995-04-19 Allen Jones James Oil-slick containment

Also Published As

Publication number Publication date
WO1996031235A1 (fr) 1996-10-10
JPH10501556A (ja) 1998-02-10
AU5504996A (en) 1996-10-23
NZ306483A (en) 1998-08-26
FR2732605A1 (fr) 1996-10-11
EP0765170A1 (fr) 1997-04-02
MX9606195A (es) 1998-06-28
HUP9700037A3 (en) 2002-04-29
FR2732605B1 (fr) 1997-05-16
CA2192473A1 (en) 1996-10-10
US6126938A (en) 2000-10-03
HUP9700037A2 (hu) 1998-10-28
NO965207D0 (no) 1996-12-05

Similar Documents

Publication Publication Date Title
NO965207L (no) Sammensetning for indusering av mukosal immunrespons
NO972781L (no) Aerosolformuleringer av peptider og proteiner
DE69332518T2 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
NO953182D0 (no) Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
HUP0101017A2 (hu) Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére
DE69518334T2 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
NO20006194D0 (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
NO20063853L (no) Kombinasjonsterapi for osteoporose
NO20003775L (no) FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner
SE9704869D0 (sv) New pharmaceutical formulaton II
DE69523587D1 (de) Fluticasonpropionat-formulierungen
TR200001977T2 (tr) Lipofilik glukokortikosteroit içeren miseller ihtiva eden bileşimler
NO975709L (no) Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter
PT918507E (pt) Formulacoes em aerossol
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
NO990498L (no) 19-nor-cholansteroider som neurokjemiske initiatorer av forandring i human, hypotalamisk funksjon
FR2763592B1 (fr) Nouveaux derives glycosyles des ginkgolides, leur application en tant que medicaments et compositions pharmaceutiques les contenant
HUP9800829A2 (hu) Kollagén alapú módszerek és készítmények az immunrendszer által közvetített betegségek kezelésére
AU1227700A (en) Method for the production of purified invasin protein and use thereof
DE69623464T2 (de) Modifizierte kojibioside analoge

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application